HeraMED

Company Overview

Snapshot

Founded in October 2011 by Tal Slonim and David Groberman, HeraMED operates with 11–50 employees. The company has raised a total of $23.76 million across 14 funding rounds and is publicly traded on the ASX. In November 2019, HeraMED's HeraBEAT device received 510(k) clearance from the FDA, a significant regulatory milestone for its connected pregnancy monitoring solutions.

Business overview

HeraMED is a technology startup developing connected pregnancy monitoring solutions for home use, focusing on fetal well-being and parental assurance. Its core products include HeraBEAT, a medically accurate, smartphone-based fetal heartbeat monitor, and HeraCARE, a digital platform designed to enable a new model of care for women throughout pregnancy. The company also has future products like the EchoBEAT line and ORION, an AI-powered pregnancy monitoring system developed in collaboration with the Mayo Clinic. HeraMED operates in the Health Tech & Life Sciences sector, serving markets globally with its digital healthcare and medical device offerings.

Strategic signal

In September 2020, HeraMED partnered with US-based eCare21, a strategic move that expands its reach into the US healthcare market. This collaboration is crucial for HeraMED as it aims to integrate its HeraCARE and HeraBEAT solutions into broader telehealth services, signaling an acceleration of its market penetration and a validation of its remote monitoring technology within the evolving digital health landscape.

Company Intelligence Q&A

What was a key regulatory achievement for HeraMED's HeraBEAT device?

In November 2019, HeraMED's HeraBEAT device received 510(k) clearance from the FDA, enabling its use as a medically accurate, smartphone-based fetal heartbeat monitor in the United States.

What strategic partnership did HeraMED form in September 2020?

In September 2020, HeraMED partnered with US-based eCare21 to expand its presence in the US healthcare market and integrate its connected pregnancy monitoring solutions with telehealth services.

When did HeraMED become publicly listed?

HeraMED became publicly listed on the ASX in December 2018, following an initial public offering.

What was the outcome of HeraMED's Full Year 2024 earnings?

HeraMED reported a Full Year 2024 earnings loss of AU$1.03 per share, compared to a loss of AU$0.025 in FY 2023, as announced in March 2025.

What research collaboration did HeraMED announce in July 2020?

In July 2020, HeraMED announced a new research collaboration with the Mayo Clinic, which also approved a clinical study of HeraMED's HeraBEAT device in December 2020.